Adlai Nortye (ANL) Competitors $1.77 -0.12 (-6.56%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. CRVS, ACB, IMMP, AURA, CGC, TSVT, ITOS, TERN, GLUE, and LFCRShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Corvus Pharmaceuticals (CRVS), Aurora Cannabis (ACB), Immutep (IMMP), Aura Biosciences (AURA), Canopy Growth (CGC), 2seventy bio (TSVT), iTeos Therapeutics (ITOS), Terns Pharmaceuticals (TERN), Monte Rosa Therapeutics (GLUE), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Corvus Pharmaceuticals Aurora Cannabis Immutep Aura Biosciences Canopy Growth 2seventy bio iTeos Therapeutics Terns Pharmaceuticals Monte Rosa Therapeutics Lifecore Biomedical Corvus Pharmaceuticals (NASDAQ:CRVS) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability. Which has higher valuation and earnings, CRVS or ANL? Corvus Pharmaceuticals has higher earnings, but lower revenue than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.98-3.70Adlai Nortye$5M13.73-$104.87MN/AN/A Do insiders and institutionals hold more shares of CRVS or ANL? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend CRVS or ANL? Corvus Pharmaceuticals currently has a consensus target price of $15.00, indicating a potential upside of 313.22%. Adlai Nortye has a consensus target price of $9.00, indicating a potential upside of 383.87%. Given Adlai Nortye's higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CRVS or ANL? Corvus Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Does the media prefer CRVS or ANL? In the previous week, Corvus Pharmaceuticals had 6 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Corvus Pharmaceuticals and 0 mentions for Adlai Nortye. Corvus Pharmaceuticals' average media sentiment score of 0.92 beat Adlai Nortye's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Positive Adlai Nortye Neutral Does the MarketBeat Community favor CRVS or ANL? Corvus Pharmaceuticals received 287 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 61.97% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29561.97% Underperform Votes18138.03% Adlai NortyeOutperform Votes8100.00% Underperform VotesNo Votes Is CRVS or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Adlai Nortye N/A N/A N/A SummaryCorvus Pharmaceuticals beats Adlai Nortye on 8 of the 13 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.63M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E RatioN/A8.9226.7619.71Price / Sales13.73252.24389.71117.54Price / CashN/A65.8538.2534.62Price / BookN/A6.466.784.50Net Income-$104.87M$143.98M$3.23B$248.18M7 Day Performance-1.59%2.03%1.51%0.23%1 Month Performance-4.12%4.11%10.03%12.39%1 Year Performance-85.41%-2.87%16.65%7.07% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.4765 of 5 stars$1.77-6.6%$9.00+409.6%-85.4%$65.17M$5M0.00127Gap DownCRVSCorvus Pharmaceuticals2.3996 of 5 stars$4.05-8.6%$16.33+303.3%+66.5%$276.08MN/A-4.3530Analyst ForecastHigh Trading VolumeACBAurora Cannabis0.6327 of 5 stars$5.06+4.3%N/A-26.8%$272.64M$320.81M101.221,340IMMPImmutep1.4139 of 5 stars$1.87+1.1%$8.50+354.5%-39.9%$270.17M$5.14M0.002,021Analyst UpgradeAURAAura Biosciences2.6153 of 5 stars$5.35+2.3%$22.75+325.2%-14.2%$268.70MN/A-3.0950Earnings ReportInsider TradeCGCCanopy Growth0.9052 of 5 stars$1.46+11.5%$2.00+37.0%-82.2%$268.44M$276.75M-0.383,150Trending NewsGap UpTSVT2seventy bio1.5618 of 5 stars$5.00+0.2%$4.25-15.0%N/A$266.15M$37.86M-2.69440Positive NewsITOSiTeos Therapeutics2.9738 of 5 stars$6.92+3.9%$25.50+268.5%-54.4%$264.86M$35M-2.2090Analyst RevisionHigh Trading VolumeTERNTerns Pharmaceuticals4.0969 of 5 stars$3.02-0.7%$18.38+508.4%-51.1%$263.76MN/A-2.5640News CoveragePositive NewsGLUEMonte Rosa Therapeutics2.1813 of 5 stars$4.27+4.4%$15.50+263.0%-6.6%$262.65M$75.62M-2.3390Positive NewsAnalyst DowngradeLFCRLifecore Biomedical1.2515 of 5 stars$6.98+0.1%$8.00+14.6%+8.2%$258.43M$130.31M-12.46690Analyst Forecast Related Companies and Tools Related Companies Corvus Pharmaceuticals Alternatives Aurora Cannabis Alternatives Immutep Alternatives Aura Biosciences Alternatives Canopy Growth Alternatives 2seventy bio Alternatives iTeos Therapeutics Alternatives Terns Pharmaceuticals Alternatives Monte Rosa Therapeutics Alternatives Lifecore Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANL Stock Free ANL Stock Alerts